TRIAL DETAIL

Sorafenib for Imatinib/Sunitinib-failed GIST

Drug:
Trial Name:
Sorafenib for Imatinib/Sunitinib-failed GIST
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 11/01/2009
Age of Trial (yrs) 15.5
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor
Strategy:
Block KIT + Block KIT Signal Path
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
2009-08-102
Sponsor:
Samsung Medical Center
Patient Contact:
Se Hoon Park, MD 82234101767 hematoma@skku.edu Hwangbo Sunyoung 82230108771 syhb80@amc.seoul.kr
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results
 

Drug Information
Nexavar.com
 
NexConnect patient support program
 
Nexavar REACH program for insurance coverage
 
Nexavar prescribing information (PDF)
 
What do I need to know about my Nexavar Therapy? (English) PDF Bayer Brochure
 
What do I need to know about my Nexavar Therapy? (Spanish) PDF
 
What do I need to know about my Nexavar Therapy? (Chinese) PDF
 
What do I need to know about my Nexavar Therapy? (Korean) PDF
 
Managing the side effects of sorafenib and sunitinib (PDF)
 
What do I need to know about my Nexavar Therapy? (Japanese) PDF
 
What do I need to know about my Nexavar Therapy? (Vietnamese) PDF
 
Sorafenib fourth-line treatment in imatinib, sunitinib and nilotinib resitant metastatic GIST: A retrospective analysis
 
Scientific Discussion - EMEA 2006 (PDF) - See PDF under the Assessment history tab.
 
NCI Cancer Bullentin-Trial Suggests New Treatment Option for Gastrointestinal Stromal Tumors
 
Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
 
Abstract - Sorafenib induces growth suppression in mouse model of GIST
 
Hand-Foot Skin Reaction (HFSR) - Nexavar website
 
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving VEGF inhibitors (PDF)
 
Skin tumors induced by sorafenib; Paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1
 
Bienvenido a Nexavar Latinoamérica
 
Patient Information - FDA approved patient labeling (PDF)
 
Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib (full text article/PDF)
 
A Phase II Trial of Intrapatient Dose-Escalated Sorafenib in Patients With Metastatic Renal Cell Carcinoma
 
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
 
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study (full text article)
 
Pancreatic Atrophy — A New Late Toxic Effect of Sorafenib
 
Sorafenib induces cachexia by impeding transcriptional signaling of the SET1/MLL complex on muscle-specific genes
 
How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling
 

Trial Sites

Name
Address
City
State
Zip
Country
Seoul
Republic of Korea